Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).

Next Previous
X
Search
Trial Profile

A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1208 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 16 May 2018 Results of dose-escalation part of two studies including this study published in the British Journal of Cancer.
    • 20 Apr 2016 Pooled analysis of 2 studies, including 32 patients from this trial and 35 patients from another study [see CTP 700216938] were presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 23 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top